Nice post, thumbs up from me. I'll check out the s/sheets but I too prefer a real options approach when it comes to biotechs. I also like to fit a distribution to the range of outcomes, especially if it's long tailed to get a better feel with what you're dealing with. Important to do this to fit in with the utility curve your dealing with (risk averse, risk seeking etc).
BTA looks good. Each hurdle they overcome is one step up in the value chain. I'm not 100% convinced listing on the NASDAQ will provide an immediate revaluation but I'm sure over the medium term as the story unfolds, and if positive, that a steady flow of ASX script will be converted to ADR's.
Management must be happy with the outcome. Good on them, a real success for the Aussie Biotech sector. This should be applauded on the news rather than giving free advertising to a terrible performance by charlie sheen!
I'm happy to hold and agree there are some short term dates to look for. Also worth looking out for RSV deal, HRV progress (late this year), lead compound selection for superbug etc.
Cheers.
BTA Price at posting:
$1.37 Sentiment: Buy Disclosure: Held
